These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 26026101)
21. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389 [TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048 [TBL] [Abstract][Full Text] [Related]
23. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Schoolmeester JK; Howitt BE; Hirsch MS; Dal Cin P; Quade BJ; Nucci MR Am J Surg Pathol; 2014 Feb; 38(2):176-88. PubMed ID: 24418852 [TBL] [Abstract][Full Text] [Related]
24. Perivascular epithelioid tumor (PEComa) of the falciform/ broad ligament. Ryś J; Karolewski K; Pudełek J; Kruczak A; Wasilewska A; Vogelgesang M; Kojs Z Pol J Pathol; 2008; 59(4):211-5. PubMed ID: 19391488 [TBL] [Abstract][Full Text] [Related]
25. Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. Russell CM; Buethe DD; Dickinson S; Sexton WJ Ann Clin Lab Sci; 2014; 44(1):91-8. PubMed ID: 24695481 [TBL] [Abstract][Full Text] [Related]
26. Medical treatment of advanced malignant perivascular epithelioid cell tumors. Fabbroni C; Sbaraglia M; Sanfilippo R Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317 [TBL] [Abstract][Full Text] [Related]
27. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Martignoni G; Pea M; Reghellin D; Gobbo S; Zamboni G; Chilosi M; Bonetti F Arch Pathol Lab Med; 2010 Jan; 134(1):33-40. PubMed ID: 20073603 [TBL] [Abstract][Full Text] [Related]
28. Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor). Machado I; Cruz J; Lavernia J; Rayon JM; Poveda A; Llombart-Bosch A Int J Surg Pathol; 2017 Sep; 25(6):543-549. PubMed ID: 28459168 [TBL] [Abstract][Full Text] [Related]
29. Targeting bone metastatic cancer: Role of the mTOR pathway. Bertoldo F; Silvestris F; Ibrahim T; Cognetti F; Generali D; Ripamonti CI; Amadori D; Colleoni MA; Conte P; Del Mastro L; De Placido S; Ortega C; Santini D Biochim Biophys Acta; 2014 Apr; 1845(2):248-54. PubMed ID: 24508774 [TBL] [Abstract][Full Text] [Related]
30. A huge malignant perivascular epithelioid cell tumor (PEComa) of the uterine cervix and vagina. Natella V; Merolla F; Giampaolino P; Bifulco G; Mainenti PP; Insabato L Pathol Res Pract; 2014 Mar; 210(3):186-8. PubMed ID: 24331571 [TBL] [Abstract][Full Text] [Related]
31. mTOR inhibition, a potential novel approach for bronchial carcinoids. Dong M; Yao JC Endocr Relat Cancer; 2011 Jun; 18(3):C15-8. PubMed ID: 21427170 [TBL] [Abstract][Full Text] [Related]
32. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313 [TBL] [Abstract][Full Text] [Related]
33. Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Akumalla S; Madison R; Lin DI; Schrock AB; Yakirevich E; Rosenzweig M; Balar AV; Frampton GM; Edgerly C; Erlich RL; Miller VA; Ganesan S; Ross JS; Ali SM Oncology; 2020; 98(12):905-912. PubMed ID: 32966992 [TBL] [Abstract][Full Text] [Related]
34. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Li J; Xue L; Hao H; Han Y; Yang J; Luo J Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902 [TBL] [Abstract][Full Text] [Related]
35. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Wysocki PJ Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082 [TBL] [Abstract][Full Text] [Related]
36. Current and future directions in mammalian target of rapamycin inhibitors development. Fasolo A; Sessa C Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441 [TBL] [Abstract][Full Text] [Related]